In contrast to trastuzumab, the anti-tumor activity of lapatinib is based solely on the intracellular inhibition of cell-signaling by competing with ATP for the ATP-binding domain in the cytoplasmic tail of the tyrosine kinase receptor – mostly HER2 and EGFR [34, 35]. This evidence concerns the gene EGFR and neoplasm.